Monday, June 13th marks a huge milestone for the Alopecia community with the first FDA-approved treatment for the condition.
Olumiant (baricitinib), as described by NAAF, “belongs to a class of medications known as Janus kinase (JAK) inhibitors. Oluminant™ is approved by the FDA for adults with (moderate to severe) alopecia areata. Olumiant™, from manufacturer Eli Lilly and Company.”
For a drug to receive FDA approval, extensive clinical trials must be carried out. Typically receiving approval takes around ten months. With the first FDA-approved treatment, the future is incredibly promising for the Alopecia community.
Olumiant is a prescription treatment. For those interested in learning more, consult a board-certified dermatologist. Check out the official announcement from the FDA
